Cheng Ying, Liang Shiqing, Zhang Shuhan, Hui Xiaoyan
Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, China.
School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong 999077, China.
Biomedicines. 2024 Jul 4;12(7):1474. doi: 10.3390/biomedicines12071474.
Obesity is a complex medical condition caused by a positive imbalance between calorie intake and calorie consumption. Brown adipose tissue (BAT), along with the newly discovered "brown-like" adipocytes (called beige cells), functions as a promising therapeutic tool to ameliorate obesity and metabolic disorders by burning out extra nutrients in the form of heat. Many studies in animal models and humans have proved the feasibility of this concept. In this review, we aim to summarize the endeavors over the last decade to achieve a higher number/activity of these heat-generating adipocytes. In particular, pharmacological compounds, especially agonists to the β3 adrenergic receptor (β3-AR), are reviewed in terms of their feasibility and efficacy in elevating BAT function and improving metabolic parameters in human subjects. Alternatively, allograft transplantation of BAT and the transplantation of functional brown or beige adipocytes from mesenchymal stromal cells or human induced pluripotent stem cells (hiPSCs) make it possible to increase the number of these beneficial adipocytes in patients. However, practical and ethical issues still need to be considered before the therapy can eventually be applied in the clinical setting. This review provides insights and guidance on brown- and beige-cell-based strategies for the management of obesity and its associated metabolic comorbidities.
肥胖是一种复杂的医学状况,由卡路里摄入与消耗之间的正向失衡所致。棕色脂肪组织(BAT)以及新发现的“类棕色”脂肪细胞(即米色细胞),作为一种有前景的治疗手段,可通过以热量形式消耗多余营养物质来改善肥胖和代谢紊乱。在动物模型和人体中的许多研究都证实了这一概念的可行性。在本综述中,我们旨在总结过去十年为增加这些产热脂肪细胞数量/活性所做的努力。特别地,对药物化合物,尤其是β3肾上腺素能受体(β3-AR)激动剂,就其提高BAT功能及改善人体代谢参数的可行性和有效性进行综述。另外,BAT同种异体移植以及来自间充质基质细胞或人诱导多能干细胞(hiPSC)的功能性棕色或米色脂肪细胞移植,使得增加患者体内这些有益脂肪细胞的数量成为可能。然而,在该疗法最终应用于临床之前,仍需考虑实际和伦理问题。本综述为基于棕色和米色细胞的肥胖及其相关代谢合并症管理策略提供见解和指导。